WELL: FY25 Deep Dive
FY25 revenue $10.67B (+36%) — Senior Housing Operating Portfolio (SHOP) drove 13 consecutive quarters of same-store NOI growth >20%, with Q4 +20.4%. Total portfolio Q4 same-store NOI growth 15%. SHOP now ~70% of in-place NOI. 22% FFO/share growth FY25. Outpatient Medical $7.2B sale announced (closing 2026). 9 of 9 covered analyst actions Feb-March were PT raises.
Key Takeaways
Welltower closed fiscal 2025 (calendar year ended December 31, 2025) at $10.67 billion of revenue, up 36% YoY — the cleanest senior-housing-led growth print in healthcare REITs. The structural read is that the Senior Housing Operating Portfolio (SHOP) — the company's owned-and-operated assisted living and memory care portfolio — produced 13 consecutive quarters of same-store NOI growth exceeding 20% (Q4 +20.4%). Total portfolio same-store NOI growth in Q4 was 15%. Organic revenue growth in SHOP was ~10% driven by 400bp occupancy gains plus healthy rate growth; Q4 operating margins expanded 270bp. Net income was $937M ($1.39 diluted EPS); FFO/share growth of 22% was the headline FY25 result. The strategic move of the year: Welltower announced a $7.2 billion sale of an 18 million sq ft Outpatient Medical portfolio (structured to retain $1.2B preferred equity stake at 8% coupon, closing 2026), pivoting toward becoming a pure-play rental housing platform for the aging population. Capital allocation: zero buybacks; $1.88B in dividends. Free cash flow $2.85B (+30% from $2.20B FY24). Total debt $21.4B (vs $16.8B FY24, expanded for $1.2B HC-One UK acquisition + $5.2B Barchester UK acquisition + ongoing senior housing acquisitions). 9 analysts cover with consensus Buy: 9 Buy / 0 Hold / 0 Sell, consensus PT $232.78, range $215-$245. Every covered analyst action between February and March 2026 was a PT raise — uniformly bullish on the SHOP / FFO compounding thesis.
Main business structure
Welltower is a healthcare REIT focused on senior housing + outpatient medical + skilled nursing. Effective FY25, the strategic emphasis has shifted overwhelmingly toward Senior Housing Operating (SHOP) and away from Outpatient Medical (in process of divestiture).
Major segments:
- SHOP (Senior Housing Operating Portfolio) ~70% of in-place NOI: assisted living, memory care, independent living — owned + operated by Welltower (vs leased to operators)
- Senior Housing Triple-Net ~10%: same property type, but leased long-term to operators with fixed rent
- Outpatient Medical ~15-20% (being divested): medical office buildings, healthcare services real estate
- Long-Term Post-Acute ~5%: skilled nursing facilities
SHOP segment — the growth engine
13 consecutive quarters of same-store NOI growth >20%. Drivers:
- Occupancy gains: 400bp YoY in Q4 (sustained 400bp+ for multiple quarters); aging-demographic tailwind + post-COVID normalization
- Rate growth: ~6-8% annual rent increases; revenue per occupied room (RevPOR) consistently above expense per occupied room (ExpPOR) growth
- Operating leverage: 270bp Q4 margin expansion; UK portfolio +550bp YoY occupancy ramp drove 10.4% UK revenue growth
Welltower has been actively transforming the company into a "pure-play rental housing platform for the aging population" — Shankh Mitra (CEO) language. Welltower 3.0 is the operations-and-technology-first platform with new talent (Jeff Stott CTO, Russ Simon EVP of Operations) and Welltower Business System (WBS) initiatives.
Strategic actions FY25
- Outpatient Medical divestiture announced: $7.2B sale of 18M sqft portfolio. Welltower retains $1.2B preferred equity at 8% coupon. Resulting $1.9B gain on sale. Exiting Outpatient Property Management business.
- HC-One UK acquisition ($1.2B): expanded UK senior housing platform
- Barchester UK acquisition ($5.2B): the largest UK senior housing acquisition in recent years
- YTD investment activity: $33B across the year ($23B+ incremental in late 2025)
- Private Funds Management business: launched in 2025; structural new earnings stream
- Q4 dividend +17% increase
Geographic mix. US (~75%), UK (~15-20% post-HC-One/Barchester), Canada (~5%). UK exposure has grown materially in FY25.
Customer concentration. 60+ senior housing operator partners across SHOP + triple-net portfolios. Top 5 operators ~25% of NOI; no 10% threshold concentration disclosure.
Scale anchors. ~2,000 properties globally. ~$180B capital base + insurance asset base. 200K+ senior housing units across portfolio. Credit rating A by S&P + Moody's.
Key core metrics (3-year trend)
1. Revenue + SHOP-led acceleration
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Revenue ($B) | 6.48 | 7.85 | 10.67 |
| YoY | — | +21% | +36% |
The +36% FY25 print is the largest single-year revenue growth at scale for any healthcare REIT — driven by both organic SHOP NOI growth + acquisition contribution (HC-One, Barchester, ongoing US senior housing acquisitions).
2. SHOP same-store NOI growth — the 13Q streak
| Quarter | SHOP same-store NOI growth |
|---|---|
| Multiple quarters Q1 FY24-Q4 FY25 | >20% YoY (13 consecutive) |
| Q4 FY25 | +20.4% |
The 13-quarter streak is the cleanest empirical signal of the senior housing demand-supply mismatch — limited new construction during 2020-2024 + aging demographic + post-COVID occupancy normalization combined.
3. FFO per share + earnings
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Net income ($M) | 340 | 952 | 937 |
| Diluted EPS | $0.66 | $1.57 | $1.39 |
| FFO/share growth | — | — | +22% |
GAAP net income vs FY24 reflects accounting treatment of acquisitions; FFO/share (the REIT-relevant metric) grew 22%.
4. Capital allocation
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Dividends ($B) | 1.26 | 1.55 | 1.88 |
| Buybacks ($B) | 0 | 0 | 0 |
| Net debt ($B, end-FY) | ~16 | ~17 | ~21 |
| Total debt ($B) | 16.1 | 16.8 | 21.4 |
Debt expansion of $4.6B reflects acquisition financing (HC-One + Barchester + others). Net debt to adjusted EBITDA stayed below 3x. No buybacks — REIT capital allocation favors acquisition + dividend growth model.
Market evaluation
Sell-side coverage (as of April 27, 2026). 9 analysts cover the stock.
| Rating | Count |
|---|---|
| Buy / Outperform / Overweight | 9 |
| Hold | 0 |
| Sell | 0 |
Price targets. Consensus $232.78, range $215 (low: Morgan Stanley, OW) to $245 (high: Citi, Buy).
Recent analyst activity (Feb-March 2026). 9 covered actions captured — all 9 were PT raises, uniformly bullish:
- Citigroup: $215 → $245 on Feb 18 — +$30, Street-high
- Keybanc: $210 → $240 on Feb 24 — +$30
- UBS: $228 → $240 on Feb 12 — Buy maintained
- Scotiabank: $214 → $236 on March 2 — Sector OP maintained
- RBC Capital: $207 → $230 on Feb 24 — Outperform
- Mizuho: $216 → $231 on March 4 — OP
- Wells Fargo: $218 → $228 on March 26 — OW
- Cantor Fitzgerald: $204 → $230 on Feb 12 — OW
- Morgan Stanley: $200 → $215 on Feb 18 — OW (Street-low)
Pattern: every action raised PT $10-$30 with rating maintains. Zero downgrades. The post-Feb earnings cycle was uniformly bullish.
Buy-side positioning. WELL is a core healthcare REIT holding paired with VTR (Ventas) + DOC (Healthpeak) in healthcare REIT baskets. Trades at premium NAV multiple to peers on SHOP momentum + UK expansion + transformation thesis. Short interest below 2% of float.
FY25 corporate structure: pure-play senior housing pivot in motion
FY25 is the year Welltower's structural transformation crystallized — exiting Outpatient Medical via $7.2B sale, doubling down on UK senior housing via HC-One ($1.2B) + Barchester ($5.2B) acquisitions, and launching a private funds management business. The 13-quarter streak of SHOP same-store NOI growth >20% — Q4 +20.4% — is the cleanest single data point in healthcare REIT for the demographic-led senior housing thesis. Total portfolio same-store NOI Q4 +15%, FFO/share +22%, with operating margins expanding 270bp YoY. The Q4 dividend +17% increase signals management confidence in continued FCF generation. The two FY26 watch items: (1) does the SHOP same-store NOI growth pace moderate as occupancy approaches structural ceilings (current ~85-87% in many markets, with theoretical ceiling near 92-93%), or sustain through CY26 on UK ramp + rate growth; (2) does the Outpatient Medical divestiture close as planned (mid-2026) and what's the FY26 capital deployment for SHOP acquisitions. The Q1 FY26 earnings print this week is the proximate event for measuring continued SHOP momentum + UK integration progress + 2026 FFO guide.